She gave people medical test results that were incorrect. Say what you want about PE, the medical diagnostics firms they own provide accurate test results to patients.
We have an entire insurance industry that makes money denying care to Americans while they die, or are those okay deaths since it's done under the confines of shareholder value?
Because the only force keeping costs down is insurance death panels. One of our problems is that we don’t have enough death panels compared to our peers.
They do, they’re TPMs and PMs. If you’re a development team at Amazon stressing over MBRs, you’ve failed to give those people the tools to pull important metrics themselves.
Yeah, Amazon didn’t let its low margin retail business prevent them from taking high margins in AWS. I’m not sure why it is assumed Stripe would stay low margin.
I saw. Most entry-level ebikes have at least 10ah * 36v batteries; a few lightweight models have 7ah. So this has about half the battery capacity of the cheapest ebikes.
> Which sort of affirms the mantra, "If you can't prove causation, try to prove correlation."
There’s already tons of correlation published for semaglutide lowering rates of dementia. This study is an effort at helping find the mechanism beyond the generally also known correlation that losing weight lowers rates of dementia.
> This is a Novo Nordisk-funded study focusing on predictive biomarkers rather than real-world dementia cases
You act like all this is hidden, but the title of the article and the list of authors makes this self-evident.
> Novo Nordisk's actual dedicated clinical trials for Alzheimer's completely failed to show that semaglutide stops cognitive decline
Sure, but the EVOKE studies were focused on something that could be sold as a product covered by insurance: semaglutide to those who had already developed Alzheimer’s. It is widely agreed the trial failed because it was a population already diagnosed with dementia. There’s lots of studies not funded by Novo that show semiglutatide has reduced the incidence of dementia in the diabetes population. Novo knows that running a general study on whether semaglutide reduces dementia in a non-diagnosed population is useless to their bottom line because insurance will never pay for everyone to take the drug.
It wasn't even funded in the way funding a study usually means. That an entity handed over money to a research group. The study was done by employers in their work time for their salary. Its a Novo Nordisk study, and as you say its right there in the open. Pointing an llm against the paper to (wrongly) realize this is a real tragedy of literacy.
The article title is fine. The title posted to HN (and other forums) should have outro or intro:
In a study funded by X, "Semaglutide linked to lower predicted dementia risk"
Or
"Semaglutide linked to lower predicted dementia risk", in a study funded by X.
This is a fair addendum that should be added when cross posting across websites. It need not be in the original link title. And this type of declaration should really follow most cross posted titles where a perceived bias/skepticism might otherwise be triggered without that knowledge being included. It's an explicit declaration upfront of potential conflicts.
I had an interesting internal debate the other day about whether farm fields were more natural than fields of solar panels. (Ignore fields that have both for now). To me, a tilled field that is being chemically fertilized and tilled is at this point just as far removed from the former native state.
reply